366-367 / 1173
ESTRO
9%
24%
51%
12.3 m
154
69.6 Gy/ 1.2 Gy b.i.d.
4%
20%
46%
11.4 m
152
60.0 Gy/ 2.0 Gy
4yrs
2yrs
1yr
MST
n
Schedule
Survival
Hyperfractionation in NSCLC
RTOG 83-11/ ECOG 4588, Phase III, NSCLC II-IIIB
Sause et al.,
J. Natl. Cancer Inst.
87: 198-205, 1995
Komaki et al.,
IJROBP
39: 537-544, 1997
n.s.
Third arm neoadj. ChT